#Germany #Discovery Life Sciences #Kassel #Luminos Comprehensive #IVDR Compliance

Discovery Life Sciences Launches Luminos® Comprehensive

A significant advancement in oncology trials has been made with the launch of Luminos® Comprehensive by Discovery Life Sciences. This innovative offering features a 164-gene pan-tumor comprehensive genomic profiling (CGP) panel specifically validated for use on FFPE tissue. Importantly, it adheres to the standards of the In Vitro Diagnostic Regulation (IVDR) and is deployed in-house at their state-of-the-art facility in Kassel, Germany.

Fast and Reliable Results

One of the standout features of Luminos® Comprehensive is its efficiency in report generation. With results being delivered in just 7 to 10 business days, it promises to streamline the operational processes for pharmaceutical sponsors and Contract Research Organizations (CROs) involved in European oncology clinical trials. Typically, many laboratories struggle to meet the stringent demands of the IVDR-compliant testing requirement, often resulting in delayed timelines. In contrast, this new launch aims to fill that crucial gap.

Addressing the Needs of Oncology Trials

The launch of this panel comes at a time when meeting the EU's regulatory requirements for oncology studies has proven to be demanding. Many existing labs faced challenges claiming Health Institution status or lacked validated in-house genomic panels, leading to wait times of three to four weeks for test results. Such delays not only hinder trial progress but also affect patient enrollment.

Scott Reid, the VP and Global Head of Companion Diagnostics at Discovery Life Sciences, pointed out the pressing need for accessible and reliable IVDR-compliant tests. The introduction of Luminos® Comprehensive is timely and aims to enhance enrollment rates in oncology studies by promising rapid turnaround times which are essential in today's fast-paced clinical research environment.

Beyond the EU - Global Relevance

The compliance implications of Luminos® Comprehensive extend beyond Europe, affecting any sponsor enrolling patients at trial sites within the EU, regardless of the sponsor's headquarters. This factor is crucial for US-based biotechs and others that are navigating the complexities of European regulations, particularly given the growing emphasis on data sovereignty and in-EU genomic data processing. The facility in Kassel is designed to meet these rigorous requirements, thus optimizing both speed and compliance.

Comprehensive Gene Coverage

Luminos® Comprehensive covers an impressive array of 164 genes that include essential oncogenes and tumor suppressor genes, vital pathways, and therapeutic targets. The panel encompasses markers such as EGFR, KRAS, BRAF, and HER2, which are crucial for many ongoing research projects. For sponsors, this comprehensive coverage reduces logistical complications and additional testing costs at the enrollment stage, making the trial initiation process smoother.

Pricing for the new genomic profiling service is designed to be straightforward, allowing sponsors and CROs to efficiently obtain quotes. In addition, the Kerala facility is not only focused on performance; it is engineered to support ongoing advancements in oncology trials.

Future Developments

Discovery Life Sciences is also planning the launch of a liquid biopsy panel, known as Luminos® Liquid, which is expected to be available in Fall 2026. This panel will complement the work of Luminos® Comprehensive by enabling targeted genomic analysis through cell-free DNA and RNA, further enhancing the clinical applications of molecular profiling.

Conclusion

Discovery Life Sciences will showcase Luminos® Comprehensive at the upcoming 2026 ASCO Annual Meeting, highlighting its commitment to supporting the foundation of precision medicine in oncology. With its advanced genomic capabilities and compliance to the latest regulations, Luminos® Comprehensive sets a new standard for genomic testing in clinical trials, catering to the urgent needs of the biopharma industry.